Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021;11(s2):S129-S134.
doi: 10.3233/JPD-212563.

Bringing Advanced Therapy Medicinal Products (ATMPs) for Parkinson's Disease to the Clinic: The Investigator's Perspective

Roger A Barker  1   2 , Emma V Cutting  1 , Danielle M Daft  1
Affiliations
Review

Bringing Advanced Therapy Medicinal Products (ATMPs) for Parkinson's Disease to the Clinic: The Investigator's Perspective

Roger A Barker et al. J Parkinsons Dis. 2021.

Abstract

There is much excitement around the use of advanced therapy medicinal products (ATMPs), including cell and gene treatments, in Parkinson's disease (PD). However, taking an ATMP to clinical trials in patients with PD is complex. As such it is important from an investigator's perspective that they ask themselves two key questions before embarking on such work: firstly, why are you doing it, and, secondly, do you understand what is needed to conduct a clinical trial with that product. In this article, we briefly discuss these two questions.

Keywords: ATMP; Parkinson’s disease; clinical trial; gene therapy; regulations; stem cells.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to report.

References

    1. Julian K, Yuhasz N, Rai W, Salerno JA, Imitola J (2020) Complications from “stem cell tourism” in neurology. Ann Neurol 88, 661–668. - PubMed
    1. Sugarman J, Barker RA, Charo RA (2019) A professional standard for informed consent for stem cell therapies. JAMA 322, 1651–1652. - PubMed
    1. Sugarman J, Barker RA, Kerridge I, Lysaght T, Pellegrini G, Sipp D, Tanner C (2018) Tackling ethical challenges of premature delivery of stem cell-based therapies: ISSCR 2018 Annual Meeting Focus Session Report. Stem Cell Rep 11, 1021–1025. - PMC - PubMed
    1. Buttery PC, Barker RA (2020) Gene and cell-based therapies for Parkinson’s disease: Where are we? Neurotherapeutics 30, 1–24. - PMC - PubMed
    1. Kordower JH (2016) AAV2-neurturin for Parkinson’s disease: What lessons have we learned? Methods Mol Biol 1382, 485–490. - PubMed